Business Wire

ARTHUR-D.-LITTLE

Share
New Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation

Whatever the success of climate change mitigation measures, companies and society will need to adapt to a changing world. To aid business climate change adaptation strategies, Arthur D. Little (ADL)’s Blue Shift Institute today published We’re doomed, now what?, an in-depth report that sets out five potential scenarios for adaptation and highlights relevant technologies to focus on.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627698200/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation (Graphic: Business Wire)

The report is based on extensive analysis, interviews with over 40 international experts, surveys of business leaders, and was created in close collaboration with the United Nation’s (UN’s) World Intellectual Property Organization (WIPO).

It works on a “+3°C by 2100” outcome for climate change, based on projections by the Intergovernmental Panel on Climate Change (IPCC) and uses this to underpin five potential, non-exclusive scenarios for the future of climate change adaptation:

  • Green Communities: A resource-scarce world in which grassroots initiatives flourish, for lack of more ambitious projects; there is a pull towards greater decentralization, circularity, and frugality
  • Lonely at the top: Highly concentrated and competitive industries in which market leaders spearhead adaptation to build competitive advantage and keep satisfying consumers, while operating under increasing constraints
  • Wild Green West: A creative chaos in which private adaptation initiatives sprout everywhere, fueled by private capital and hype, with no overarching strategy or consistency
  • Don’t Look Up: A bleak future in which neither customers nor finance institutions have adjusted to the new climate reality, leaving nothing but quick fixes and crisis management
  • Adaptation Surge: A world in which adaptation is the norm and the new currency, resetting expectations, creating new markets and new needs for differentiation, and possibly overengineering

For each of these futures the report outlines the functional expectations and relevant technologies to drive adaptation. Alongside this, it includes “no regret” solutions, enabling technologies, and capabilities that will be vital, whatever the future brings, and that companies should invest in now.

Dr. Albert Meige, Global Director of Blue Shift at Arthur D. Little, comments: “When faced with prospective technology choices, executives often need to address three challenges: complexity, speed and cognition. Adaptation to climate change is no different. It is complex because climate impacts are local, multifactorial and highly variable; and also because there is a myriad of adaptation technologies available. By modeling potential scenarios we aim to cut through this complexity, providing CEOs with a clear guide to the potential technologies that their adaptation will require.”

Dr. Peter Oksen, Senior Program Officer at the World Intellectual Property Organization (WIPO) GREEN, comments: “This report offers a refreshing new angle to climate action, namely that of businesses and their priorities for adapting to a challenging future. It provides the scenario-based context for the technologies outlined by WIPO GREEN, underscoring the essential role of innovation in forging a sustainable future. By detailing the functional expectations and key technologies necessary for adaptation, it highlights the need to integrate technological advancements within our business, economic and policy frameworks to effectively combat climate change.”

We’re doomed, now what? can be accessed here: https://tinyurl.com/4w35xahm

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627698200/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye